4P Pharma Delta 4 sign agreement to identify and develop treatments for rare autoimmune chronic liver disease
4P-Pharma, a French clinical stage biotechnology company, and Delta 4, an Austrian digital drug development company, announced the signing of a collaboration agreement. Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available. Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signalling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta 4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta 4

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!